parogrelil

**Parogrelil** is a small molecule drug that acts as a selective **phosphodiesterase 3 (PDE3) inhibitor** and calcium channel inhibitor. Initially developed by **Nissan Chemical Corp.**, it demonstrates bronchodilating and anti-inflammatory effects, inhibits human platelet aggregation and rat aortic contraction in vitro, and improves walking distance in models of peripheral vascular disease. It reached **Phase 3** trials for **intermittent claudication** but was discontinued, with earlier Phase 2 exploration in **peripheral vascular diseases**, **asthma**, and related conditions.[1][2][3][5]

Other names

parogrelil hydrochloride